Cas:1353637-44-1 6-chloro-1-(oxan-2-yl)pyrazolo[4,3-c]pyridine manufacturer & supplier

Chemical Name:6-chloro-1-(oxan-2-yl)pyrazolo[4,3-c]pyridine

CAS.NO:1353637-44-1

Synonyms:6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine;QC-182;RR82

Molecular Formula:C₁₁H₁₂ClN₃O

Molecular Weight:237.68500

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:39.94000

Exact Mass:237.06700

LogP:2.78380

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,RR82 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,QC-182 Use and application,6-chloro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-c]pyridine technical grade,usp/ep/jp grade.

Related News: According to Plexxikon, GSK scientists were only able to make Tafinlar after talks with Plexxikon about a potential partnership; although those talks never turned into a licensing deal, GSK apparently channeled that information and created a rival drug. 7-bromo-5-methyl-1-oxido-1,2,4-benzotriazin-1-ium-3-amine manufacturers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. Enantiomer of Mirogabalin suppliers The license, granted by the Medicines and Healthcare Products Regulatory Agency (MHRA), allows Onyx to support API projects from pre-clinical studies to low volume commercial manufacture. 3-(1-butoxyethenyl)cyclohex-2-en-1-one vendor & factory The European Commission (EC) has approved MSD and Bayer’s Verquvo for the treatment of symptomatic chronic heart failure in patients with reduced ejection fraction.,According to Plexxikon, GSK scientists were only able to make Tafinlar after talks with Plexxikon about a potential partnership; although those talks never turned into a licensing deal, GSK apparently channeled that information and created a rival drug.